Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 15 February 2007, Vol. 109, No. 4, pp. 1692-1700.
Prepublished online as a Blood First Edition Paper on October 5, 2006; DOI 10.1182/blood-2006-07-037077.


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Tables
Right arrow All Versions of this Article:
blood-2006-07-037077v1
109/4/1692    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhan, F.
Right arrow Articles by Shaughnessy, J. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhan, F.
Right arrow Articles by Shaughnessy, J. D., Jr
Related Collections
Right arrow Immunobiology
Right arrow Neoplasia
Right arrow Gene Expression
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

NEOPLASIA

Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis

Fenghuang Zhan1, Bart Barlogie1, Varant Arzoumanian1, Yongsheng Huang1, David R. Williams1, Klaus Hollmig1, Mauricio Pineda-Roman1, Guido Tricot1, Frits van Rhee1, Maurizio Zangari1, Madhav Dhodapkar2, and John D. Shaughnessy, Jr1

1 Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock; 2 Laboratory of Tumor Immunology and Immunotherapy, Rockefeller University, New York, NY

Monoclonal gammopathy of undetermined significance (MGUS) can progress to multiple myeloma (MM). Although these diseases share many of the same genetic features, it is still unclear whether global gene-expression profiling might identify prior genomic signatures that distinguish them. Through significance analysis of microarrays, 52 genes involved in important pathways related to cancer were differentially expressed in the plasma cells of healthy subjects (normal plasma-cell [NPC]; n = 22) and patients with stringently defined MGUS/smoldering MM (n = 24) and symptomatic MM (n = 351) (P < .001). Unsupervised hierarchical clustering of 351 patients with MM, 44 with MGUS (24 + 20), and 16 with MM from MGUS created 2 major cluster branches, one containing 82% of the MGUS patients and the other containing 28% of the MM patients, termed MGUS-like MM (MGUS-L MM). Using the same clustering approach on an independent cohort of 214 patients with MM, 27% were found to be MGUS-L. This molecular signature, despite its association with a lower incidence of complete remission (P = .006), was associated with low-risk clinical and molecular features and superior survival (P < .01). The MGUS-L signature was also seen in plasma cells from 15 of 20 patients surviving more than 10 years after autotransplantation. These data provide insight into the molecular mechanisms of plasma-cell dyscrasias.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
BloodHome page
S. Blotta, P. Tassone, R. H. Prabhala, P. Tagliaferri, D. Cervi, S. Amin, J. Jakubikova, Y.-T. Tai, K. Podar, C. S. Mitsiades, et al.
Identification of novel antigens with induced immune response in monoclonal gammopathy of undetermined significance
Blood, October 8, 2009; 114(15): 3276 - 3284.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J.-L. Harousseau, M. Attal, and H. Avet-Loiseau
The role of complete response in multiple myeloma
Blood, October 8, 2009; 114(15): 3139 - 3146.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
A. Anguiano, S. A. Tuchman, C. Acharya, K. Salter, C. Gasparetto, F. Zhan, M. Dhodapkar, J. Nevins, B. Barlogie, J. D. Shaughnessy Jr, et al.
Gene Expression Profiles of Tumor Biology Provide a Novel Approach to Prognosis and May Guide the Selection of Therapeutic Targets in Multiple Myeloma
J. Clin. Oncol., September 1, 2009; 27(25): 4197 - 4203.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A. Hoering, J. Crowley, J. D Shaughnessy Jr, K. Hollmig, Y. Alsayed, J. Szymonifka, S. Waheed, B. Nair, F. van Rhee, E. Anaissie, et al.
Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols
Blood, August 13, 2009; 114(7): 1299 - 1305.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
G. Fan, Y. Fan, N. Gupta, I. Matsuura, F. Liu, X. Z. Zhou, K. P. Lu, and C. Gelinas
Peptidyl-Prolyl Isomerase Pin1 Markedly Enhances the Oncogenic Activity of the Rel Proteins in the Nuclear Factor-{kappa}B Family
Cancer Res., June 1, 2009; 69(11): 4589 - 4597.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
O. Landgren, R. A. Kyle, R. M. Pfeiffer, J. A. Katzmann, N. E. Caporaso, R. B. Hayes, A. Dispenzieri, S. Kumar, R. J. Clark, D. Baris, et al.
Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study
Blood, May 28, 2009; 113(22): 5412 - 5417.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
B. M. Weiss, J. Abadie, P. Verma, R. S. Howard, and W. M. Kuehl
A monoclonal gammopathy precedes multiple myeloma in most patients
Blood, May 28, 2009; 113(22): 5418 - 5422.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
W. Xiong, X. Wu, S. Starnes, S. K. Johnson, J. Haessler, S. Wang, L. Chen, B. Barlogie, J. D. Shaughnessy Jr, and F. Zhan
An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma
Blood, November 15, 2008; 112(10): 4235 - 4246.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
S. Y. Kristinsson, T. R. Fears, G. Gridley, I. Turesson, U.-H. Mellqvist, M. Bjorkholm, and O. Landgren
Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma
Blood, November 1, 2008; 112(9): 3582 - 3586.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
B. Barlogie, M. Pineda-Roman, F. van Rhee, J. Haessler, E. Anaissie, K. Hollmig, Y. Alsayed, S. Waheed, N. Petty, J. Epstein, et al.
Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities
Blood, October 15, 2008; 112(8): 3115 - 3121.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
B. Barlogie, F. van Rhee, J. D. Shaughnessy Jr, J. Epstein, S. Yaccoby, M. Pineda-Roman, K. Hollmig, Y. Alsayed, A. Hoering, J. Szymonifka, et al.
Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease
Blood, October 15, 2008; 112(8): 3122 - 3125.
[Abstract] [Full Text] [PDF]


Home page
J Natl Cancer Inst MonogrHome page
A. Dib, A. Gabrea, O. K. Glebov, P. L. Bergsagel, and W. M. Kuehl
Characterization of MYC Translocations in Multiple Myeloma Cell Lines
J Natl Cancer Inst Monographs, July 1, 2008; 2008(39): 25 - 31.
[Abstract] [Full Text] [PDF]


Home page
Mayo Clin Proc.Home page
O. Landgren, L. R. Goldin, N. E. Caporaso, R. A. Kyle, and S. V. Rajkumar
Genetic Predisposition for Monoclonal Gammopathy of Undetermined Significance-reply-I
Mayo Clin. Proc., May 1, 2008; 83(5): 602 - 603.
[Full Text] [PDF]


Home page
BloodHome page
U.-M. Fagerli, R. U. Holt, T. Holien, T. K. Vaatsveen, F. Zhan, K. W. Egeberg, B. Barlogie, A. Waage, H. Aarset, H. Y. Dai, et al.
Overexpression and involvement in migration by the metastasis-associated phosphatase PRL-3 in human myeloma cells
Blood, January 15, 2008; 111(2): 806 - 815.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. Haessler, J. D. Shaughnessy Jr., F. Zhan, J. Crowley, J. Epstein, F. van Rhee, E. Anaissie, M. Pineda-Roman, M. Zangari, K. Hollmig, et al.
Benefit of Complete Response in Multiple Myeloma Limited to High-Risk Subgroup Identified by Gene Expression Profiling
Clin. Cancer Res., December 1, 2007; 13(23): 7073 - 7079.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
P. Greipp
Progression risk for MGUS and SMM
Blood, October 1, 2007; 110(7): 2226 - 2226.
[Full Text] [PDF]


Home page
NEJMHome page
H. K. Prasad, F. Zhan, J. Shaughnessy, D. Focosi, A. T. Andrews, R. A. Kyle, and S. V. Rajkumar
Smoldering Multiple Myeloma
N. Engl. J. Med., September 6, 2007; 357(10): 1048 - 1050.
[Full Text] [PDF]


Home page
BloodHome page
F. van Rhee, V. Bolejack, K. Hollmig, M. Pineda-Roman, E. Anaissie, J. Epstein, J. D. Shaughnessy Jr, M. Zangari, G. Tricot, A. Mohiuddin, et al.
High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis
Blood, August 1, 2007; 110(3): 827 - 832.
[Abstract] [Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020